SAB Biotherapeutics, Inc. (SABSW) — Operating Income
| Fiscal Year | Operating Income | Change YoY |
|---|---|---|
| 2025 | -$48.95M | -14.1% |
| 2024 | -$42.91M | -12.7% |
| 2023 | -$38.08M | -31.7% |
| 2022 | -$28.92M | -115.9% |
| 2021 | -$13.39M | -165.2% |
| 2020 | $20.56M | — |
| Fiscal Year | Operating Income | Change YoY |
|---|---|---|
| 2025 | -$48.95M | -14.1% |
| 2024 | -$42.91M | -12.7% |
| 2023 | -$38.08M | -31.7% |
| 2022 | -$28.92M | -115.9% |
| 2021 | -$13.39M | -165.2% |
| 2020 | $20.56M | — |